| Am. J. Biomed. Sci. 2009, 1(3), 242-249; doi: 10.5099/aj090300242 |
An Overview on Relation between the
Bradykinin System and Hypertension and Diabetes |
|
J. N. Sharma* |
|
Department
of Applied Therapeutics, Faculty of Pharmacy, Health Sciences Centre, Kuwait University, Kuwait |
|
*Corresponding Author: |
|
J. N. Sharma |
|
Department of Applied Therapeutics |
|
Faculty of Pharmacy, Health Sciences Centre |
|
Kuwait University, P.O. Box 24923 |
|
Safat 13110, Kuwait |
|
Email:
j.n.sharma@hsc.edu.kw |
|
Abstract It is proposed here that a
deficiency of BK might be a significant factor in the pathophysiology of
hypertension and diabetes. In this regard, it is suggested that the role of
renal BK is to excrete the excess sodium. Therefore, a reduction in the
generation of renal BK may be the cause for the development of hypertension as
a result of the accumulation of sodium in the body. Thus, the development of a
compound having renal kallikrein-like activity may serve the purpose of
excreting excessive sodium from the kidney in the treatment of hypertension.
Transgenic mice over-expressing renal tissue kallikrein were hypotensive and
that administration of aprotinin, a tissue kallikrein inhibitor, restored the
BP of the transgenic mice. Recently, it has been proposed that tissue
kallikrein gene delivery into various hypertensive models exhibits protection,
such as reduction in high blood pressure, attenuation of cardiac hypertrophy,
inhibition of renal damage and stenosis. This may indicate the future
therapeutic aspect of kallikrein gene therapy for hypertension, cardiovascular
and renal pathology. Keywords: bradykinin system; diabetes;
hypertension; overview. Download the full article (PDF)
|
© American Journal of Biomedical Sciences 2007.
All Rights Reserved.